XML 53 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue- Narrative (Details)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 102 Months Ended
May 28, 2021
USD ($)
Aug. 03, 2020
USD ($)
shares
Jan. 07, 2018
USD ($)
Oct. 31, 2014
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Mar. 31, 2023
USD ($)
Oct. 01, 2014
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Expenses related to collaboration agreement         $ 124,187,000 $ 128,339,000 $ 250,870,000 $ 259,315,000      
Unrealized gain (loss) on available-for-sale investments         26,000 (909,000) 2,069,000 (5,711,000)      
Total revenue         13,690,000 5,362,000 20,857,000 6,071,000      
Cost of product revenue         1,025,000 0 1,583,000 0      
Product Revenue                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Total revenue         13,365,000 0 19,656,000 0      
Milestone Payments                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Expenses related to collaboration agreement           0   0      
BeiGene Agreement                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Non-refundable, non-creditable up-front fee     $ 10,000,000                
Milestone payments     $ 123,000,000                
Termination of contract, period after first commercial sale of product     10 years                
Period required for notice of termination of contract     60 days                
Performance obligation, compensation to be earned     $ 500,000                
Milestone payments earned         0 0 0 0      
Royalty revenue         0 0 0 0      
BeiGene Agreement | Maximum                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Royalty percentage rate (up to)     0.20                
BeiGene Agreement | Licenses of Intellectual Property                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Performance obligation, compensation to be earned     $ 9,500,000                
Pfizer Agreement                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Termination of contract, period after first commercial sale of product       10 years              
Period required for notice of termination of contract       60 days              
Pfizer Agreement | Development Milestone Payments                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Potential development milestone payments                     $ 9,300,000
Development milestone payments         0   1,000,000     $ 10,500,000  
Pfizer Agreement | Sales Milestone Payments                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Potential development milestone payments                     $ 337,000,000
Pfizer Agreement | Milestone Payments - First Commercial Sale of KRAZATI                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Potential development milestone payments         15,000,000   15,000,000        
Pfizer Agreement | Royalties                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Cost of product revenue         900,000   1,400,000        
ORIC Pharmaceuticals Agreement                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Stock received as part of stock issuance and license agreements (shares) | shares   588,235                  
License agreement, period of transfer restrictions   18 months                  
License agreement, period of agreement after first commercial sale   10 years                  
ORIC Pharmaceuticals Agreement | Level 3                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
One-time non-cash payment   $ 11,400,000                  
Zai Agreement                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Period required for notice of termination of contract 12 months                    
Milestone payments earned         0 5,000,000   5,000,000      
Termination of contract, period after first commercial sale of product 10 years                    
Up-front fee received $ 65,000,000                    
Transaction price of arrangement 66,600,000                    
Zai Agreement | Licenses of Intellectual Property                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue recognized                 $ 66,600,000    
Income tax recovery                 $ 3,300,000    
Zai Agreement | Manufacturing Supply Services                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue recognized         300,000 400,000 1,200,000 1,100,000      
Zai Agreement | Sales Milestone Payments                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue from performance obligation expected to be earned 180,000,000                    
Zai Agreement | Development and Regulatory Milestone Payments                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue from performance obligation expected to be earned $ 93,000,000                    
Zai Agreement | Royalties                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Royalty revenue         $ 0 $ 0 $ 0 $ 0